Scholars Central

OtherPublished 13 Jul 2016

Targeted therapy for hepatocellular carcinoma: current status and future direction

Authors: Stephen L Chan, Tony Mok

Clinical Investigation

Volume 3 · Issue 1 · Pages 83

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Following the proof of evidence on the use of sorafenib in patients with advanced hepatocellular carcinoma (HCC), targeted therapy has become an important element in management of advanced HCC. Novel targeted therapies are designed to inhibit the aberrant signaling pathways or oncogenic mechanism at a molecular level with an aim to improve the clinical outcome. An increasing number of targeted agents have been tested in HCC in the clinical setting in the past few years. This review aims to summarize the current status of clinical development of targeted therapy in HCC focusing on novel agents targeting angiogenesis, signal transduction and epigenetic dysregulation of tumors. The future direction of drug development for HCC will also be explored.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Investigation.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Stephen L Chan”
  • BylineArticles whose byline prints “Tony Mok”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels